cytidine has been researched along with Cancer of Pancreas in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Enoki, Y; Imoto, S; Ito, C; Matsumoto, K; Moroi, Y; Taguchi, K; Tokuda, R; Yamasaki, K | 1 |
| Chen, H; Feng, Z; Han, D; Jiang, L; Li, K; Liang, H; Liang, J; Ma, Y; Peng, C; Qin, K; Shen, B; Shi, M; Zhao, S | 1 |
| Leung, E; Lozano Hernandez, L; Reginald-Opara, JN; Svirskis, D; Tang, M; Wang, H; Wu, Z | 1 |
| Bhutkar, S; Dukhande, V; Patel, K; Patki, M; Saraswat, A | 1 |
| Babiker, H; Benaim, E; Borad, MJ; Bullock, AJ; Burhani, N; Elquza, E; Heaton, C; Hicks, LG; Mahadevan, D; Ocean, AJ; Peterson, C; Schlegel, PJ | 1 |
| An, Y; Cai, H; Chen, X; Duan, Y; Liu, S; Sun, D; Wu, X; Yang, Y; Zhang, Y | 1 |
| El Hassouni, B; Funel, N; Giovannetti, E; Infante, J; Mantini, G; Peters, GJ; Ricci, C | 1 |
| Fritzer-Szekeres, M; Giessrigl, B; Golakoti, T; Graser, G; Grusch, M; Jaeger, W; Krupitza, G; Lackner, A; Saiko, P; Schuster, H; Somepalli, V; Steinmann, MT; Szekeres, T | 1 |
| Angel, A; Congiatu, C; Gavazza, F; Jones, PA; Marquez, VE; McGuigan, C; Siddiqui, MA; Valente, R; Yoo, CB | 1 |
| Barten-Van Rijbroek, AD; Kal, HB; Leen, R; Rodermond, HM; Van Bree, C; Van Kuilenburg, AB | 1 |
| Fujioka, A; Fukushima, M; Kazuno, H; Matsuda, A; Sakamoto, K; Sasaki, T | 1 |
| Dietze, O; Hahn, EG; Hauser-Kronberger, C; Herold, C; Leu, T; Neureiter, D; Ocker, M; Zopf, S | 1 |
| Leen, R; Medema, J; Rodermond, H; van Bree, C; van Kuilenburg, A | 1 |
| Fujioka, A; Fukushima, M; Kato, T; Kazuno, H; Matsuda, A; Murakami, Y; Ohshimo, H; Sasaki, T; Shimamoto, Y | 1 |
1 trial(s) available for cytidine and Cancer of Pancreas
| Article | Year |
|---|---|
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2022 |
13 other study(ies) available for cytidine and Cancer of Pancreas
| Article | Year |
|---|---|
Trimethoxy Trityl Groups as a Potent Substituent for Anti-cancer Cytidine Analog Prodrugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytidine; Humans; Mice; Pancreatic Neoplasms; Prodrugs | 2022 |
The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA.
Topics: Acetyltransferases; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytidine; Gene Expression Regulation, Neoplastic; Humans; N-Terminal Acetyltransferases; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Long Noncoding; RNA, Messenger; Ubiquitin-Specific Proteases | 2022 |
Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery.
Topics: Animals; Cell Line, Tumor; Cytidine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Liposomes; Pancreatic Neoplasms; Rats | 2021 |
In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms | 2021 |
Identification of ENTPD8 and cytidine in pancreatic cancer by metabolomic and transcriptomic conjoint analysis.
Topics: Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cytidine; Female; Gene Expression Profiling; Humans; Male; Metabolomics; Middle Aged; Pancreatic Neoplasms | 2018 |
Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cytidine; Female; Humans; Male; Pancreatic Neoplasms; RNA, Messenger; Uridine Kinase | 2019 |
Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.
Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Cycle; Cell Line, Tumor; Cytidine; DNA; Free Radical Scavengers; Gallic Acid; Humans; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Picrates; Proto-Oncogene Mas; Ribonucleotide Reductases; Stilbenes | 2013 |
Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine.
Topics: Adenocarcinoma; Amides; Cytidine; DCMP Deaminase; DNA Methylation; Dose-Response Relationship, Drug; Gene Silencing; Genes, p16; Humans; Molecular Structure; Pancreatic Neoplasms; Phosphoric Acids; Reverse Transcriptase Polymerase Chain Reaction; Stereoisomerism; Thymidylate Synthase; Tumor Cells, Cultured | 2008 |
Cyclopentenyl cytosine has biological and anti-tumour activity, but does not enhance the efficacy of gemcitabine and radiation in two animal tumour models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Cytidine; Cytidine Triphosphate; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Rats; Rats, Inbred BN | 2009 |
Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytidine; Deoxycytidine; Deoxyribonucleotides; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Ribonucleotides; RNA, Messenger; Xenograft Model Antitumor Assays | 2005 |
Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Differentiation; Cell Proliferation; Cytidine; DNA, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Tumor Cells, Cultured; Vorinostat | 2007 |
Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cytidine; Cytidine Triphosphate; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents | 2008 |
Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Cytidine; Female; Humans; Lung Neoplasms; Male; Pancreatic Neoplasms; Rats; Rats, Inbred F344; Rats, Nude; Stomach Neoplasms; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |